A novel inhaled phosphodiesterase 4 inhibitor (CHF6001) reduces the allergen challenge response in asthmatic patients

Abstract CHF6001 is an inhaled phosphodiesterase 4 (PDE4) inhibitor in development for the treatment of obstructive lung diseases. We investigated the efficacy and safety of CHF6001 using the allergen challenge model in a double blind, placebo controlled, 3-way cross-over study. Thirty six atopic as...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Pulmonary pharmacology & therapeutics 2016-10, Vol.40, p.1-6
Hauptverfasser:	Singh, D, Leaker, B, Boyce, M, Nandeuil, M.A, Collarini, S, Mariotti, F, Santoro, D, Barnes, P.J
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Inhalation Adult Allergen challenge Allergens - immunology Asthma - drug therapy Asthma - immunology Asthma - physiopathology CHF6001 Cross-Over Studies Dose-Response Relationship, Drug Double-Blind Method Dry Powder Inhalers Female Forced Expiratory Volume Humans Male Medical Education para-Aminobenzoates - administration & dosage para-Aminobenzoates - adverse effects para-Aminobenzoates - pharmacology PDE4 inhibitor Phosphodiesterase 4 Inhibitors - administration & dosage Phosphodiesterase 4 Inhibitors - adverse effects Phosphodiesterase 4 Inhibitors - pharmacology Pulmonary/Respiratory Sputum Sulfonamides - administration & dosage Sulfonamides - adverse effects Sulfonamides - pharmacology Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!